Journal article
Selective and reversible inhibitors of ubiquitin-specific protease 7: a patent evaluation (WO2013030218).
- Abstract:
-
The invention described in this review (WO2013030218) relates to compounds based on the quinazolin-4-one scaffold, their process of preparation and applications to inhibit the ubiquitin-specific protease 7 (USP7), a deubiquitinating enzyme (DUB), which is considered a potentially important new drug target for treating cancer and immunological disorders. Data are presented indicating that these small-molecule compounds are useful as selective and reversible inhibitors of USP7 in vitro and also...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Publisher:
- Informa Healthcare
- Journal:
- Expert opinion on therapeutic patents
- Volume:
- 24
- Issue:
- 5
- Pages:
- 597-602
- Publication date:
- 2014-05-01
- DOI:
- EISSN:
-
1744-7674
- ISSN:
-
1354-3776
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:446663
- UUID:
-
uuid:08c8d826-f1ea-43d1-b8cf-b0cd8ef641ed
- Local pid:
- pubs:446663
- Source identifiers:
-
446663
- Deposit date:
- 2014-01-30
Terms of use
- Copyright date:
- 2014
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record